Skip to main content
OpenTrials
Completed

NCT Number: NCT05164601

Prognosis of Treated Acute Coronary Syndrome Patients: a Multicenter Study

The MPCS-ACS Study (Multicenter Prospective Cohort Study on Acute Coronary Syndrome) is a comprehensive, forward-looking research project designed to evaluate the prognostic outcomes of patients diagnosed with acute coronary syndrome (ACS) who declined coronary artery bypass grafting (CABG) and underwent percutaneous coronary intervention (PCI) instead. Leveraging a multicenter approach, the study aims to collect data from a diverse patient population, thereby enhancing the generalizability and clinical relevance of its findings.

Upon enrollment, detailed information is gathered, including demographic data, clinical history, and key biochemical markers. The study also documents the various medication regimens prescribed during hospitalization to assess their influence on patient outcomes. A key feature of MPCS-ACS is its rigorous follow-up protocol, which involves regularly monitoring patients after discharge to track recovery progress and the occurrence of any subsequent cardiovascular events.

This methodical approach is designed to generate valuable insights into the long-term prognosis of ACS patients treated with PCI, ultimately contributing to the refinement of therapeutic strategies and improving the standard of care across all participating centers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Coronary Syndrome Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year–79 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China

Loading trial locations.

About this study

The Multicenter Acute Coronary Syndrome Prognosis Cohort Study (MPCS-ACS) is a comprehensive, longitudinal research initiative designed to evaluate the prognostic outcomes of patients diagnosed with acute coronary syndrome (ACS) across diverse healthcare settings. Conducted in collaboration with multiple hospitals, this study aims to collect and analyze data from ACS patients admitted between June 1, 2016, and May 31, 2021.

The study will gather an extensive range of variables, including therapeutic interventions, biochemical markers relevant to ACS management, as well as key demographic and clinical history data. By analyzing these factors, the study seeks to gain a deeper understanding of ACS treatment practices during the study period and assess their clinical efficacy.

A robust follow-up protocol is a cornerstone of MPCS-ACS, featuring routine evaluations conducted every six to twelve months after patient discharge. Follow-ups will incorporate both in-person visits and telecommunication to accommodate participants unable to return to the hospital. This dual approach is designed to maximize participant retention and ensure high-quality data collection, thereby enhancing the study's validity and impact.

Through its rigorous methodology and collaborative framework, the MPCS-ACS aims to identify key prognostic factors and outcomes for ACS patients. The ultimate goal is to inform the optimization of care strategies and elevate the standards of cardiovascular treatment across diverse healthcare systems.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women aged between 18 and 79 years.
  • Patients diagnosed with Acute Coronary Syndrome (ACS), including Unstable Angina (UA) and Acute Myocardial Infarction (AMI), based on typical clinical symptoms, changes in electrocardiographic (ECG) readings, and elevated cardiac biomarkers.
  • Patients who underwent coronary angiography confirming coronary artery stenosis and opted for PCI treatment instead of coronary artery bypass grafting (CABG).
  • Patients who are under long-term follow-up.

Exclusion criteria

  • Patients with rheumatic heart disease, valvular heart disease, or congenital heart disease.
  • Patients with malignant tumors or hematologic diseases.
  • Patients with severe liver or kidney dysfunction or pulmonary heart disease.
  • Patients with a life expectancy of less than one year due to terminal illnesses such as advanced cancer or chronic kidney disease requiring dialysis.
  • Patients whose health is severely impacted by acute infections.

Treatment and study plan

No Intervention - Observational Only

Other

Clinical Follow-Up

Primary outcomes

  1. Death

    Time frame: 10 years

    All-cause mortality, Cardiac mortality

Secondary outcomes

  1. Major adverse cardiovascular events (MACE)

    Time frame: 10 years

    cardiac death, non-fatal myocardial infarction, significant aortic pathologies including aortic dissection and rupture of aortic aneurysms, episodes of unstable angina necessitating medical intervention, hospitalization for acute heart failure classified as Killip Class IV, and revascularization of the target vessel.

  2. Major adverse cardiovascular and cerebrovascular events (MACCE）

    Time frame: 10 years

    cardiac death, non-fatal myocardial infarction, aortic events such as aortic dissection and aortic aneurysm rupture, episodes of unstable angina requiring medical intervention, hospitalization for acute heart failure assessed at Killip Class IV, target vessel revascularization, cerebrovascular events encompassing ischemic stroke, hemorrhagic stroke, transient ischemic attacks (TIAs) and subarachnoid hemorrhage.

  3. revascularization of the target vesse

    Time frame: 10 years

    Revascularization of the target vessel was performed using percutaneous coronary intervention (PCI).

  4. episodes of unstable angina necessitating medical intervention

    Time frame: 10 years

    Episodes of unstable angina requiring medical intervention were managed with urgent therapeutic measures.

  5. hospitalization for acute heart failure classified as Killip Class IV

    Time frame: 10 years

    hospitalization for acute heart failure classified as Killip Class IV

  6. non-fatal myocardial infarction

    Time frame: 10 years

    non-fatal myocardial infarction

  7. cerebrovascular events

    Time frame: 10 years

    ischemic stroke, hemorrhagic stroke, transient ischemic attacks (TIAs) and subarachnoid hemorrhage.

Sponsors and collaborators

Lead sponsor

Xiang Xie

Other

Collaborators

  • Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University
  • The Third Affiliated Hospital of Jinzhou Medical University

Registry information

Official study title

A Multicenter, Prospective Cohort Study Evaluating the Prognosis of Patients with Acute Coronary Syndrome

Acronym: MPCS-ACS

Important dates

Study start
2016
Primary completion
2021
Study completion
2023
First posted
Dec 20, 2021
Registry last updated
Feb 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.